1
|
Pi Z, Johnson JA, Meng W, Phillips M, Schumacher WA, Bostwick JS, Gargalovic PS, Onorato JM, Generaux CN, Wang T, He Y, Gordon DA, Wexler RR, Finlay HJ. Identification of 6-Hydroxypyrimidin-4(1 H)-one-3-carboxamides as Potent and Orally Active APJ Receptor Agonists. ACS Med Chem Lett 2021; 12:1766-1772. [PMID: 34795866 DOI: 10.1021/acsmedchemlett.1c00385] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Accepted: 10/18/2021] [Indexed: 01/01/2023] Open
Abstract
The apelin receptor (APJ) is a significant regulator of cardiovascular function and is involved in heart failure and other cardiovascular diseases. (Pyr1)apelin-13 is one of the endogenous agonists of the APJ receptor. Administration of (Pyr1)apelin-13 increases cardiac output in preclinical models and humans. Recently we disclosed clinical lead BMS-986224 (1), a C3 oxadiazole pyridinone APJ receptor agonist with robust pharmacodynamic effects similar to (Pyr1)apelin-13 in an acute rat pressure-volume loop model. Herein we describe the structure-activity relationship of the carboxamides as oxadiazole bioisosteres at C3 of the pyridinone core and C5 of the respective pyrimidinone core. This study led to the identification of structurally differentiated 6-hydroxypyrimidin-4(1H)-one-3-carboxamide 14a with pharmacodynamic effects comparable to those of compound 1.
Collapse
Affiliation(s)
- Zulan Pi
- Research and Development, Bristol Myers Squibb Company, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - James A. Johnson
- Research and Development, Bristol Myers Squibb Company, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - Wei Meng
- Research and Development, Bristol Myers Squibb Company, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - Monique Phillips
- Research and Development, Bristol Myers Squibb Company, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - William A. Schumacher
- Research and Development, Bristol Myers Squibb Company, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - Jeffrey S. Bostwick
- Research and Development, Bristol Myers Squibb Company, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - Peter S. Gargalovic
- Research and Development, Bristol Myers Squibb Company, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - Joelle M. Onorato
- Research and Development, Bristol Myers Squibb Company, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - Claudia N. Generaux
- Research and Development, Bristol Myers Squibb Company, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - Tao Wang
- Research and Development, Bristol Myers Squibb Company, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - Yan He
- Research and Development, Bristol Myers Squibb Company, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - David A. Gordon
- Research and Development, Bristol Myers Squibb Company, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - Ruth R. Wexler
- Research and Development, Bristol Myers Squibb Company, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - Heather J. Finlay
- Research and Development, Bristol Myers Squibb Company, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| |
Collapse
|
4
|
Caille S, Allgeier AM, Bernard C, Correll TL, Cosbie A, Crockett RD, Cui S, Faul MM, Hansen KB, Huggins S, Langille N, Mennen SM, Morgan BP, Morrison H, Muci A, Nagapudi K, Quasdorf K, Ranganathan K, Roosen P, Shi X, Thiel OR, Wang F, Tvetan JT, Woo JCS, Wu S, Walker SD. Development of a Factory Process for Omecamtiv Mecarbil, a Novel Cardiac Myosin Activator. Org Process Res Dev 2019. [DOI: 10.1021/acs.oprd.9b00200] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Seb Caille
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Alan M. Allgeier
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Charles Bernard
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Tiffany L. Correll
- Attribute Sciences, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Andrew Cosbie
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Richard D. Crockett
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Sheng Cui
- Drug Substance Technologies, Process Development, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Margaret M. Faul
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Karl B. Hansen
- Drug Substance Technologies, Process Development, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Seth Huggins
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Neil Langille
- Drug Substance Technologies, Process Development, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Steven M. Mennen
- Drug Substance Technologies, Process Development, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Bradley P. Morgan
- Research & Nonclinical Development, Cytokinetics, 280 East Grand Avenue, South San Francisco, California 94080, United States
| | - Henry Morrison
- Drug Product Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Alexander Muci
- Research & Nonclinical Development, Cytokinetics, 280 East Grand Avenue, South San Francisco, California 94080, United States
| | - Karthik Nagapudi
- Drug Product Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Kyle Quasdorf
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Krishnakumar Ranganathan
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Philipp Roosen
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Xianqing Shi
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Oliver R. Thiel
- Drug Substance Technologies, Process Development, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Fang Wang
- Attribute Sciences, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Justin T. Tvetan
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Jacqueline C. S. Woo
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Steven Wu
- Attribute Sciences, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Shawn D. Walker
- Drug Substance Technologies, Process Development, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| |
Collapse
|